GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Sergio Amadori, Nicola Fracchiolla et al.|Blood|2019Cited by 215
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Journal of Clinical Oncology|2023Cited by 109
Overlapping features of therapy-related and de novo <i>NPM1</i>-mutated AMLJad Othman, Brunangelo Falini, Manja Meggendorfer et al.|Blood|2022Cited by 43
Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohortCarmelo Gurnari, Maria Teresa Voso, Maria Rosaria Pascale et al.|American Journal of Hematology|2023Cited by 43
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39